Retroperitoneal Sarcoma
Approximately 15-20% of soft tissue sarcomas develop in the retroperitoneum, which refers to the back of the abdomen (e.g., where the kidneys are located). Soft tissue sarcomas that grow in this region are called retroperitoneal sarcoma (RPS).
The most common type of retroperitoneal sarcoma is liposarcoma, which arises from fat. Others include leiomyosarcoma (smooth muscle), solitary fibrous tumor, undifferentiated pleomorphic sarcoma, and malignant peripheral nerve sheath tumor.
Occasionally, retroperitoneal sarcoma can cause symptoms when the tumor is compressing or involving a nerve or blood vessel. In most cases, however, retroperitoneal sarcoma presents subtly and without any alarming symptoms.
For each retroperitoneal sarcoma patient, our surgeons must individualize the treatments to achieve a safe but complete resection. Such complex operations require the expertise of a comprehensive cancer center like City of Hope.
Our patients have access to a wide variety of sarcoma clinical trials, including new chemotherapy, targeted and hormone therapies, surgical techniques, radiation approaches, and prevention strategies.
City of Hope is a nationally recognized leader in researching and treating sarcomas. Our clinicians and researchers collaborate extensively to develop and evaluate new therapies for better survival and quality-of-life outcomes.
When you come to City of Hope, you automatically gain access to an unparalleled array of support services to help you and your loved ones take each step during and after your sarcoma treatment.
Our Expertise
City of Hope treats a patient with retroperitoneal sarcoma with a multidisciplinary team of sarcoma specialists, including surgical oncologists, medical oncologists, radiation oncologists, pathologists and radiologists. In addition, we discuss cases at a weekly conference (Tumor Board) to mutually determine the best course of treatment for each patient.
Our team actively engages in research and collaboration, including conducting clinical trials to provide the most up-to-date knowledge and leading-edge treatment for retroperitoneal sarcoma patients. Our program also includes patient services (e.g., case managers, physical therapists and mental health experts) to provide full support.
City of Hope is one of the few facilities designated a comprehensive cancer center by the National Cancer Institute.
Our developments in the areas of breakthrough cancer drugs, bone marrow transplants and CAR T cell therapy are recognized internationally.
Our leadership in research and innovation continually enhances our ability to provide novel and differentiated approaches to cancer care.
